|
|
 Previous Article | Table of Contents | Next Article 
Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia
A.L. Petzer,
C.J. Eaves,
M.J. Barnett, and
A.C. Eaves
From the Terry Fox Laboratory and the Division of Hematology, British Columbia Cancer Agency and the Departments of Medical Genetics, Medicine, and Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels in the blood of some patients with chronic myeloid leukemia (CML). We now show that this population can be expanded several-fold when highly purified CD34+CD38- cells isolated from the blood of such patients are cultured for 10 days in a serum-free medium containing 100 ng/mL of Flt3-ligand and Steel factor and 20 ng/mL of interleukin-3 (IL-3) and IL-6, and granulocyte colony-stimulating factor. In similar cultures initiated with CD34+CD38- cells from CML blood samples in which all of the LTC-IC were leukemic (Ph+), Ph+ LTC-IC activity was rapidly lost both in the presence and absence of admixed CD34+CD38- cells isolated from normal marrow. Conversely, the ability of normal LTC-IC to expand their numbers was shown to be independent of the presence of Ph+LTC-IC and later types of Ph+colony-forming cell (CFC) progenitors. In contrast to the LTC-IC, CFC were consistently -a m p l i f i e d i n c u l t u r e s i n i t i a t e d w i t h C M L - d e r i v e d -CD34+CD38- cells and the additional CFC present after 10 days were, like the starting population of CFC, almost exclusively Ph+ regardless of the genotype(s) of the LTC-IC in the original CML samples. Amplification of the Ph+CFC population in these cultures showed the same factor dependence as previously demonstrated for the in vitro expansion of CFC from normal marrow CD34+CD38- cells. Ph+LTC-IC disappeared regardless of the cytokines present. Taken together these findings support a model of CML in which the leukemic stem cells are characterized by a decreased probability of self-renewal and an increased probability of differentiation. In addition, they suggest new opportunities for improving the treatment of CML using strategies that require autologous stem cell rescue.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 64-69
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. James, F. Mazurier, S. Dupont, R. Chaligne, I. Lamrissi-Garcia, M. Tulliez, E. Lippert, F.-X. Mahon, J.-M. Pasquet, G. Etienne, et al.
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
Blood,
September 15, 2008;
112(6):
2429 - 2438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Bowie, D. G. Kent, M. R. Copley, and C. J. Eaves
Steel factor responsiveness regulates the high self-renewal phenotype of fetal hematopoietic stem cells
Blood,
June 1, 2007;
109(11):
5043 - 5048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst,
May 2, 2007;
99(9):
680 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Glimm, M. Schmidt, M. Fischer, K. Schwarzwaelder, M. Wissler, S. Klingenberg, C. Prinz, C. F. Waller, W. Lange, C. J. Eaves, et al.
Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients
Blood,
August 1, 2005;
106(3):
893 - 898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia
Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors
Cancer Res.,
August 1, 2004;
64(15):
5322 - 5331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H.-J. Buhring, R. Mohle, D. Hoelzer, L. Kanz, W.-K. Hofmann, et al.
Inhibitory effect of imatinib on normal progenitor cells in vitro
Blood,
January 15, 2004;
103(2):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Strife, D. Wisniewski, C. Liu, C. L. Lambek, Z. Darzynkiewicz, R. T. Silver, and B. Clarkson
Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells
Mol. Cancer Res.,
January 1, 2003;
1(3):
176 - 185.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. H. Matsui, D. E. Gladstone, M. S. Vala, J. P. Barber, R. A. Brodsky, B. D. Smith, and R. J. Jones
The Role of Growth Factors in the Activity of Pharmacological Differentiation Agents
Cell Growth Differ.,
June 1, 2002;
13(6):
275 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
Blood,
May 15, 2002;
99(10):
3792 - 3800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study
Blood,
February 15, 2002;
99(4):
1150 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood,
February 1, 2001;
97(3):
720 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Brummendorf, T. L. Holyoake, N. Rufer, M. J. Barnett, M. Schulzer, C. J. Eaves, A. C. Eaves, and P. M. Lansdorp
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Blood,
March 15, 2000;
95(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, K. Mackenzie, P. Drullinsky, R. T. Silver, and M. A. S. Moore
Telomerase Activity and Telomere Length in Acute and Chronic Leukemia, Pre- and Post-ex Vivo Culture
Cancer Res.,
February 1, 2000;
60(3):
610 - 617.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Holyoake, X. Jiang, C. Eaves, and A. Eaves
Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia
Blood,
September 15, 1999;
94(6):
2056 - 2064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bennaceur-Griscelli, C. Tourino, B. Izac, W. Vainchenker, and L. Coulombel
Murine Stromal Cells Counteract the Loss of Long-Term Culture-Initiating Cell Potential Induced by Cytokines in CD34+CD38low/neg Human Bone Marrow Cells
Blood,
July 15, 1999;
94(2):
529 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Moore, D. N. Haylock, J.-P. Levesque, L. A. McDiarmid, L. M. Samels, L. B. To, P. J. Simmons, and T. P. Hughes
Stem Cell Factor as a Single Agent Induces Selective Proliferation of the Philadelphia Chromosome Positive Fraction of Chronic Myeloid Leukemia CD34+ Cells
Blood,
October 1, 1998;
92(7):
2461 - 2470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.C.Y. Wang, T. Lapidot, J.D. Cashman, M. Doedens, L. Addy, D.R. Sutherland, R. Nayar, P. Laraya, M. Minden, A. Keating, et al.
High Level Engraftment of NOD/SCID Mice by Primitive Normal and Leukemic Hematopoietic Cells From Patients With Chronic Myeloid Leukemia in Chronic Phase
Blood,
April 1, 1998;
91(7):
2406 - 2414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
